Theranostics Australia




Enquiry

Private Theranostics Provider in Australia

We strive to develop and provide powerful innovative therapies

Established in May 2015, we are dedicated to continuously developing and utilising targeted molecular diagnostic imaging and therapeutic agents for the diagnosis and treatment of cancers. We have a particular focus on cancers which are difficult to treat or are becoming resistant to conventional therapies. Contact us today to find out more.

Our knowledge of how to treat cancer is the culmination of years of research, education and application of the most innovative developments in the field. Our team of specialists, supported by advanced technologies at our facilities, works tirelessly to offer the most innovative cancer treatments on the market.


For more information, select a cancer type to be directed to a therapy offered by Theranostics Australia.


For modern cancer treatment and a team of specialists who care about your wellbeing, contact us today.


Lutetium-177 Octreotate therapy

Lutetium-177 Octreotate therapy is used to treat neuroendocrine tumours (NETs) that emerge from the endocrine or nervous system such as carcinoid tumours. It aims to reduce the size of the tumour(s) and stop them from multiplying, as well as to ease the associated symptoms. Read More

Lutetium-177 PSMA therapy

Lutetium-177 PSMA therapy is used for people with advanced prostate cancer. It is most often used when the disease has metastasised, and when other therapies are poorly tolerated or have failed. In certain patients, it can produce long-term remission. Read More

Radium-223 therapy

Radium-223 therapy is used for people who have prostate cancer that has spread to the bones. The therapy damages the cancer cells in the bone, leading to the tumours shrinking in size, or even disappearing altogether. It is also used to reduce pain that can be associated with bone cancer. Read More

Iodine-131 therapy

Iodine-131 therapy is a thyroid cancer treatment that uses radiation to treat either thyroid cancer or a hyperactive thyroid (thyrotoxicosis) by targeting the thyroid tissue. Read More

Yttrium-90 SIRT therapy

Yttrium-90 SIRT Therapy, or Selective Internal Radiation Therapy, is a treatment for cancers and tumours located within the liver. The aim of this treatment is to reduce the size of inoperable tumours or decrease the number of lesions in the liver. It may allow for the surgical removal of tumours, once considered inoperable. It may also stabilise the disease and prolong the life of the patient. Read More

Yttrium-90 Radiosynovectomy therapy

Yttrium-90 Radiosynovectomy therapy is a treatment for painful joints caused by arthritis or other types of joint diseases, often providing relief for sufferers. Read More




Theranostics Australia has collaborative ties to



 


TitleAuthor/sJournalDate
Salvage Radiopeptide Therapy of Advanced Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen: Efficacy and Safety in Routine PracticeKesavan M, Turner JH, Meyrick D, Yeo S, Cardaci G, and Lenzo N.Cancer Biotherapy & Radiopharmaceuticals2018 July
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate CancerLenzo N , Meyrick D and Turner J.Diagnostics2018 February
The role of 68Ga-PSMA-I&T PET/CT in the pretreatment staging of primary prostate cancerMeyrick D, Asokendaran M, Skelly LA, Lenzo NP, Henderson A.Nuclear Medicine Communications2017 November

View More

Abstract Posters – Monday 23rd April at WFNMB2018

Theranostics Australia’s Dr. Danielle Meyrick (Chief Scientific Officer) displayed TWO abstract submissions as posters yesterday in the Exhibition Hall at the #WFNMB2018 Conference.

(3) 68Ga-PSMA-PET/CT is Superior to Contrast CT in Rising PSA Post Definitive Treatment for Prostate Cancer (P140).

(4) Initial Experience with 1 year Follow Up in 22 Patients Treated with Lu-177 I&T PSMA for Advanced Prostate Cancer – Safety, Efficacy and Quality of Life (P199).

All 4 of TA’s posters from the WFNMB Conference will be made available this week.

Abstract Posters – Saturday 21st April at WFNMB2018

For delegates attending the #WFNMB2018 Conference, Theranostics Australia will be displaying 2 abstract submissions as posters today in the Exhibition Hall.

(1) Australian Two Centre Experience in First 150 Patients Using 68Ga Based Kit for the Production of 68Ga-PSMA-11 (P194).

(2) Incidental Treatment of Mycobacterium Avium Complex (MAC) Infection with 131Iodine (P064).

Breakfast Session Success (170+ Delegates)

Theranostics Australia would like to thank all 170+ delegates who attended our successful breakfast session this morning at the #WFNMB2018 Conference in Melbourne, as well as our invited speakers Prof Dale Bailey, Prof Kate Vallis, Dr Matt Harris and Dr Danielle Meyrick. We hope you enjoy the remainder of the #WFNMB2018 Conference.